Triheptanoin for the treatment of long‐chain fatty acid oxidation disorders: Final results of an open‐label, long‐term extension study
Jerry Vockley(Pittsburgh Public Schools), Antonio Nino Ramirez(Ultragenyx Pharmaceutical (United States)), Pranoot Tanpaiboon(Children's National), Kimberly A. Chapman(Children's National), Bridget Reineking(Ultragenyx Pharmaceutical (United States)), Elaine Murphy(National Hospital for Neurology and Neurosurgery), Syeda Rahman(Ultragenyx Pharmaceutical (United States)), Kathryn Ray(Ultragenyx Pharmaceutical (United States)), Amarilis Sanchez‐Valle(University of South Florida), Nicola Longo(Center for Human Genetics), Laura Rosa Pisani(Regenxbio (United States)), Barbara K. Burton(Women & Children's Hospital of Buffalo), Stephanie Grünewald(Great Ormond Street Hospital), John G. Phillips(Vanderbilt University Medical Center), Xiaoxiao Lu(Ultragenyx Pharmaceutical (United States))
Cited by 21
Related Papers
Phenylalanine hydroxylase deficiency: diagnosis and management guideline
|Genetics in Medicine|2014|718
Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia
|Orphanet Journal of Rare Diseases|2014|713
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Effects of Diet and Physical Activity Interventions on Weight Loss and Cardiometabolic Risk Factors in Severely Obese Adults
|JAMA|2010|554
Guidelines for the diagnosis and management of cystathionine beta‐synthase deficiency
|Journal of Inherited Metabolic Disease|2016|335